Literature DB >> 15350351

VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma.

Huaizeng Chen1, Dafeng Ye, Xing Xie, Bingya Chen, Weiguo Lu.   

Abstract

OBJECTIVE: To investigate the expressions of vascular endothelial growth factor (VEGF), VEGFRs and activation of signal transducers and activators of transcription (STATs) in ovarian epithelial carcinoma and the relationships among them.
METHODS: The tissue samples of 42 primary ovarian epithelial carcinoma, 29 benign ovarian tumor and 11 normal ovarian tissue were used to determine the expression of VEGF, VEGFR1, VEGFR2, P-STAT1, P-STAT3, P-STAT5 and P-STAT6 proteins by immunohistochemical staining.
RESULTS: VEGF in ovarian carcinomas was significantly higher than that in benign and normal ovarian tissues. VEGFRs expression was in agreement with VEGF expression. In tumor cells and endothelial cells of ovarian carcinomas, expressions of P-STAT3 and P-STAT5 were significantly higher than those in benign and normal ovarian tissues. In endothelial cells, the expression of VEGFR1 and P-STAT5 closely correlated with each other, as well as VEGFR2 and P-STAT3. However, in ovarian carcinoma cells, expressions of VEGF, VEGFR1 and VEGFR2 were significantly correlated with P-STAT3 and P-STAT5, but not with P-STAT1 and P-STAT6.
CONCLUSIONS: There exist overexpressions of VEGF, VEGFRs, and STAT3, STAT5 activation. Furthermore, these results indicate that VEGF secreted by ovarian carcinoma cells may activate STAT pathway via VEGFRs in ovarian carcinoma themselves.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15350351     DOI: 10.1016/j.ygyno.2004.05.056

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  52 in total

Review 1.  Investigational agents in development for the treatment of ovarian cancer.

Authors:  Shannon N Westin; Thomas J Herzog; Robert L Coleman
Journal:  Invest New Drugs       Date:  2012-06-04       Impact factor: 3.850

2.  Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

Authors:  William M Merritt; Alpa M Nick; Amy R Carroll; Chunhua Lu; Koji Matsuo; Melissa Dumble; Nicholas Jennings; Shuyun Zhang; Yvonne G Lin; Whitney A Spannuth; Aparna A Kamat; Rebecca L Stone; Mian M K Shahzad; Robert L Coleman; Rakesh Kumar; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2010-04-06       Impact factor: 6.261

Review 3.  Three important components in the regeneration of the cavernous nerve: brain-derived neurotrophic factor, vascular endothelial growth factor and the JAK/STAT signaling pathway.

Authors:  Hai-Yang Zhang; Xun-Bo Jin; Tom F Lue
Journal:  Asian J Androl       Date:  2010-12-20       Impact factor: 3.285

4.  Functional significance of VEGFR-2 on ovarian cancer cells.

Authors:  Whitney A Spannuth; Alpa M Nick; Nicholas B Jennings; Guillermo N Armaiz-Pena; Lingegowda S Mangala; Christopher G Danes; Yvonne G Lin; William M Merritt; Premal H Thaker; Aparna A Kamat; Liz Y Han; James R Tonra; Robert L Coleman; Lee M Ellis; Anil K Sood
Journal:  Int J Cancer       Date:  2009-03-01       Impact factor: 7.396

5.  Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.

Authors:  Setsuko K Chambers; Mary C Clouser; Amanda F Baker; Denise J Roe; Haiyan Cui; Molly A Brewer; Kenneth D Hatch; Michael S Gordon; Mike F Janicek; Jeffrey D Isaacs; Alan N Gordon; Raymond B Nagle; Heather M Wright; Janice L Cohen; David S Alberts
Journal:  Clin Cancer Res       Date:  2010-11-01       Impact factor: 12.531

6.  Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.

Authors:  Robert A Burger; Mark F Brady; Michael A Bookman; Bradley J Monk; Joan L Walker; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Gini F Fleming; Peter C Lim; Stephen C Rubin; Noriyuki Katsumata; Sharon X Liang
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

7.  STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastases.

Authors:  Christian Moser; Petra Ruemmele; Sebastian Gehmert; Hedwig Schenk; Marina P Kreutz; Maria E Mycielska; Christina Hackl; Alexander Kroemer; Andreas A Schnitzbauer; Oliver Stoeltzing; Hans J Schlitt; Edward K Geissler; Sven A Lang
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

Review 8.  Angiogenesis and ovarian cancer.

Authors:  César Gómez-Raposo; Marta Mendiola; Jorge Barriuso; Enrique Casado; David Hardisson; Andrés Redondo
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

9.  Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3.

Authors:  Karuppaiyah Selvendiran; Anna Bratasz; M Lakshmi Kuppusamy; Mia F Tazi; Brian K Rivera; Periannan Kuppusamy
Journal:  Int J Cancer       Date:  2009-11-01       Impact factor: 7.396

10.  Suppressors of cytokine-signaling proteins induce insulin resistance in the retina and promote survival of retinal cells.

Authors:  Xuebin Liu; Marie G Mameza; Yun Sang Lee; Chikezie I Eseonu; Cheng-Rong Yu; Jennifer J Kang Derwent; Charles E Egwuagu
Journal:  Diabetes       Date:  2008-03-20       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.